{"changeSha256":"b857e3fc8bb65a5fde53d29a61cfc02bd49ed248ca50b39779524f85103c4e8e","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.","before":"A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.","field":"Profile summary"},{"after":"A published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination report weight loss; combination results cannot be credited to cagrilintide alone. FDA states that cagrilintide has not been found safe and effective for any condition.","before":"ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.","field":"Evidence note"},{"after":"AM833, CagriSema","before":"AM833","field":"Related names"},{"after":"ctg-nct07253285-v5, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-34798060, journal-pmid-40544433, ctg-observation-nct07220759-2026-08-03-50fb10a6adbd, ctg-observation-nct07745504-2026-08-04-624035118e08","before":"ctg-nct07253285-v5","field":"Cited source records"},{"after":"Novo Nordisk A/S [sources: ctg-nct07253285-v5]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]","before":"Novo Nordisk A/S [sources: ctg-nct07253285-v5]","field":"Named organizations"},{"after":"name: ctg-nct07253285-v5; aliases: ctg-nct07253285-v5, journal-pmid-40544433; category: ctg-nct07253285-v5; status: ctg-nct07253285-v5, ctg-observation-nct07220759-2026-08-03-50fb10a6adbd, fda-unapproved-glp1-concerns-2026-r2; summary: journal-pmid-34798060, journal-pmid-40544433, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-34798060, journal-pmid-40544433, fda-unapproved-glp1-concerns-2026-r2","before":"name: ctg-nct07253285-v5; aliases: ctg-nct07253285-v5; category: ctg-nct07253285-v5; status: ctg-nct07253285-v5; summary: ctg-nct07253285-v5; evidenceNote: ctg-nct07253285-v5","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/cagrilintide/versions/3/","version":3},"id":"profile:cagrilintide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that cagrilintide cannot be used in compounding.","peptideSlugs":["cagrilintide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/cagrilintide/v2.json","sha256":"d9955e4845c35869ff27f676b78b56439c791e6d18ef6ef104b821d1aa48604c"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/cagrilintide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-unapproved-glp1-concerns-2026-r2","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","verifiedAt":"2026-11-14"},{"id":"journal-pmid-34798060","name":"The Lancet","sourceClass":"A","title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060","url":"https://doi.org/10.1016/S0140-6736(21)01751-7","verifiedAt":"2026-11-14"},{"id":"journal-pmid-40544433","name":"The New England Journal of Medicine","sourceClass":"A","title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433","url":"https://doi.org/10.1056/NEJMoa2502081","verifiedAt":"2026-11-14"}],"subject":{"slug":"cagrilintide","type":"profile"}}
